THE ESSENTIALS IN 30 SECONDS
- DCVC led the $62 million Series B, joined by new investors UC Investments, Skip Capital and Hostplus and by existing backers including Tony Fadell's Build Collective and Blackbird.
- The money is meant to fund a planned pivotal clinical trial across the University of California network and work toward FDA approval for neurovascular procedures.
- The company states that the N1 System is under development and not available for sale or clinical use in any jurisdiction.
Remedy Robotics, a San Francisco company building a robot for catheter-based procedures in blood vessels, announced on November 16 that it has raised $62 million in Series B funding. DCVC led the round. New investors are UC Investments, the University of California's investment office, Skip Capital and the Australian pension fund Hostplus. Existing backers Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures also took part.
What the N1 System is meant to do
The company's product, the N1 System, pairs catheter-driving hardware with machine-learning software. According to Remedy, the software analyses a patient's scans before a procedure so the case can be simulated in advance. During the procedure, it overlays 3D vessel maps built from those scans onto live 2D X-ray images. The system is designed to be run by a clinician at the bedside, by an operator in another location, or with growing levels of autonomy. Remedy is aiming first at neurovascular procedures such as stroke thrombectomy, and also lists coronary and peripheral vascular work as targets.
Where it stands with regulators
The N1 has no regulatory clearance. Remedy's release states that the system is under development and not available for sale or clinical use in any jurisdiction. The company says the new money will pay for a planned pivotal clinical trial across the University of California network and for work toward FDA approval for neurovascular intervention, followed by commercial deployment. It has given no trial design, enrolment target or timeline.
Remedy will also place prototype N1 units with partners, including the SVIN Mission Thrombectomy stroke-access initiative and the Australian Stroke Alliance, and keep developing its autonomy software. Co-founder and CTO Jake Sganga described the aim as moving the system toward clinical trials and "potential FDA approval".
Claims still to be tested
The company points to remote cerebral angiograms performed in 2025, which it calls the first fully remote neurointerventional procedures. An October 2025 post by DCVC said a Toronto neurosurgeon operated the robot from down the hall and from a hospital about six miles away, reporting no complications. The post did not say whether the subjects were patients or models, and it is written by an investor. Remedy also says it works with more than 100 hospitals and holds 48 patents. None of these claims amounts to evidence of safety or effectiveness, which is what the pivotal trial is meant to provide.
